了解默克尔细胞癌:致病信号传递,细胞外矩阵动力学和新型治疗方法
Maria Konstantaraki1,2, Aikaterini Berdiaki1, Monica Neagu3,4
1Department of Histology-Embryology, Medical School, University of Crete, 71003 Heraklion, Greece.
Cancers
|April 14, 2025
概括
默克尔细胞癌 (MCC) 是一种侵袭性皮肤癌,由病毒或紫外线辐射驱动. 针对瘤微环境以及免疫检查点,可以克服治疗耐药性.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
背景情况:
- 默克尔细胞癌 (MCC) 是一种罕见的,侵袭性的神经内分泌性皮肤癌.
- 它是由默克尔细胞多瘤病毒 (MCPyV) 或UV诱导的突变驱动的,激活瘤性途径.
- 像PI3K/AKT/mTOR和MAPK这样的关键信号通路促进瘤生长和存活.
研究的目的:
- 阐明瘤微环境 (TME) 在MCC进展和免疫逃生中的作用.
- 探索MCC中对免疫检查点抑制剂的耐药性机制.
- 确定针对TME的潜在治疗策略,以提高治疗疗效.
主要方法:
- 对MCC小圆蓝细胞,高线粒细胞发生率和死的组织学分析.
- TME的特征,包括免疫细胞和细胞外基质 (ECM) 组件.
- 对免疫检查点分子表达 (例如PD-L1) 和信号通路 (例如PI3K/AKT/mTOR,MAPK) 的分析.
主要成果:
- 在MCC中TME的特征是免疫抑制细胞和提升的PD-L1表达.
- 富含蛋白质甘氨酸,原体和MMPs的ECM有助于瘤入侵和免疫逃避.
- 集成因介导的信号传递有助于治疗耐药性.
结论:
- 在MCC的病原和免疫逃避中,TME起着至关重要的作用.
- 对目前的疗法,如免疫检查点抑制剂的耐药性是一个重大挑战.
- 针对TME (ECM,MMP,整合素) 的联合治疗策略可能会改善MCC患者的治疗结果.
相关概念视频
Mitogens and the Cell Cycle
6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
The Tumor Microenvironment
6.4K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.4K
MAPK Signaling Cascades
5.0K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.0K
Metastasis
5.4K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.4K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Interactions Between Signaling Pathways
6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K


